- Home
- CAVA vs PRAX Comparison
CAVA vs PRAX Comparison
Compare CAVA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAVA | PRAX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.2B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAVA | PRAX |
|---|---|---|
| Price | $71.95 | $298.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | $80.75 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 3.5M | 569.5K |
| Earning Date | 02-24-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.16 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $1,132,074,000.00 | $7,463,000.00 |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $20.42 | $14,827.76 |
| P/E Ratio | $60.87 | ★ N/A |
| Revenue Growth | 23.93 | ★ 364.98 |
| 52 Week Low | $43.41 | $26.70 |
| 52 Week High | $144.49 | $317.72 |
Technical Indicators
Market Signals| Indicator | CAVA | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 75.24 | 61.96 |
| Support Level | $67.45 | $266.93 |
| Resistance Level | $72.11 | $306.16 |
| Average True Range (ATR) | 2.45 | 16.10 |
| MACD | 0.76 | -2.70 |
| Stochastic Oscillator | 93.86 | 60.78 |
Price Performance
Historical ComparisonAbout CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.